Clinical Trial

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Study acronym: NEXUS-01
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Protocol Amendment History 2 changes
notable Trial sites expanded: 35 -> 38 locations 2026-07-21
notable Trial sites expanded: 28 -> 31 locations 2026-04-21
Trial Details
NCT Number NCT06465069
Lead Sponsor Eli Lilly and Company
Conditions Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer +6 more
Enrollment 420 participants
Start Date 2024-07-01
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-20